By Mill Chart
Last update: Nov 21, 2023
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) has caught the eye of our stock screener as an affordable growth stock. NYSE:NVO is displaying robust growth metrics and also excels in terms of profitability, solvency, and liquidity. Additionally, it appears to be reasonably priced. Let's delve into the details.
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NYSE:NVO was assigned a score of 7 for growth:
ChartMill provides a Valuation Rating to every stock, ranging from 0 to 10. This rating assesses various valuation aspects, comparing price to earnings and cash flows, while considering factors like profitability and growth. NYSE:NVO boasts a 5 out of 10:
ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NYSE:NVO has earned a 7 out of 10:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NYSE:NVO has earned a 9 out of 10:
More Affordable Growth stocks can be found in our Affordable Growth screener.
For an up to date full fundamental analysis you can check the fundamental report of NVO
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (5/17/2024, 7:17:01 PM)
After market: 131.65 -0.24 (-0.18%)131.89
-1.15 (-0.86%)
The market has flashed a green signal to investors.
Novo Nordisk's stock may look expensive today, but that may not be the case in even a year or two.
Investors want to know where 2024's top-performing pharma stocks are headed in the second half of the year for good reason.
Could Amgen be the next stock to soar due to a GLP-1 drug?
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for quality investing?
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
Back then, the company wasn't very well known to U.S. investors. That's absolutely not the case these days.
This company is serious about maintaining its leadership.
Both of these businesses are finding traction in a pair of major markets.
This mid-cap biopharma may one day be a titan of the industry.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is showing decent growth, but is still valued reasonably.